Israeli startup Kadimastem to merge With NLS Pharmaceutics
Kadimastem and NLS Limited Announce Merger
In an exciting development, shareholders of Kadimastem Ltd., an Israeli bio-pharmaceutical startup, have approved a merger with the Swiss company NLS Limited. Kadimastem, founded in 2009 and located in Ness Ziona, Israel, is known for its work in cell therapy. The company specializes in creating "off-the-shelf" cell products using Human Embryonic Stem Cells (hESCs). Meanwhile, NLS Limited, based in Zurich, Switzerland, focuses on developing treatments for rare and complex central nervous system disorders. The merger is pending approval from NLS shareholders.
Doubts Revealed
Kadimastem
Kadimastem is a company from Israel that makes medicines using special cells called Human Embryonic Stem Cells. These cells can turn into any type of cell in the body, which helps in treating diseases.
NLS Limited
NLS Limited is a company from Switzerland that works on creating treatments for rare diseases that affect the brain and nerves.
Merger
A merger is when two companies join together to become one. This helps them work better and share their resources.
Shareholder approval
Shareholders are people who own a part of a company. They need to agree or give permission for big decisions like a merger.
Human Embryonic Stem Cells
These are special cells that can grow into any type of cell in the body. They are used in medicine to help repair or replace damaged tissues.
Central nervous system disorders
These are problems that affect the brain and spinal cord, which control everything we do, like moving, thinking, and feeling.
Your email address will not be published. Required fields are marked *